Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Up 3.6% – Here’s What Happened

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s share price traded up 3.6% on Wednesday. The stock traded as high as $779.67 and last traded at $780.4880. Approximately 375,131 shares changed hands during trading, a decline of 54% from the average daily volume of 819,843 shares. The stock had previously closed at $753.12.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Jefferies Financial Group lifted their price objective on shares of Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Wells Fargo & Company lifted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Finally, Sanford C. Bernstein lifted their price target on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a “market perform” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $834.24.

Regeneron Pharmaceuticals Trading Up 3.2%

The firm has a fifty day moving average of $790.91 and a two-hundred day moving average of $720.73. The company has a market cap of $80.04 billion, a PE ratio of 19.22, a price-to-earnings-growth ratio of 1.38 and a beta of 0.16. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $12.81 earnings per share. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the transaction, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. The trade was a 8.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director owned 603 shares in the company, valued at approximately $512,550. The trade was a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,946 shares of company stock valued at $3,302,458 over the last three months. Company insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $5,682,636,000. Legal & General Group Plc bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $473,872,000. Bank of New York Mellon Corp bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $472,950,000. Deutsche Bank AG purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $323,249,000. Finally, Man Group plc purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $272,460,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.